{"transactions":[{"id":4616593,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":24155,"kind":"person","name":"Wiley Matthew T.","position":1,"cik":"0001759703","reported_name":"Wiley Matthew T.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Shares","published_at":"2026-09-14T12:30:08.000Z","date":"2026-09-14","kind":"grant","planned":false,"acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The common shares represent the third tranche of performance share units granted effective March 17, 2025, and remain subject to vesting based on the Reporting Person's continued employment through March 17, 2028. Each performance share unit represented a contingent right to receive one common share based on, and subject to, the achievement of certain clinical and regulatory milestones set forth in the Performance Share Unit Award Agreement."}],"balance_after":362133,"source":{"system":"sec-edgar","filing":"0001193125-26-389890","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000119312526389890/ownership.xml","form_type":"4"}},{"id":689330,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":24155,"kind":"person","name":"Wiley Matthew T.","position":1,"cik":"0001759703","reported_name":"Wiley Matthew T.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Shares","published_at":"2026-08-12T12:30:05.000Z","date":"2026-08-12","kind":"grant","planned":false,"acquired":true,"shares":62500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The common shares represent the second tranche of performance share units granted effective March 17, 2025, and remain subject to vesting based on the Reporting Person's continued employment through March 17, 2028. Each performance share unit represented a contingent right to receive one common share based on, and subject to, the achievement of certain clinical and regulatory milestones set forth in the Performance Share Unit Award Agreement."}],"balance_after":237133,"source":{"system":"sec-edgar","filing":"0001193125-26-345836","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000119312526345836/ownership.xml","form_type":"4"}},{"id":725561,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":24155,"kind":"person","name":"Wiley Matthew T.","position":1,"cik":"0001759703","reported_name":"Wiley Matthew T.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Shares","published_at":"2026-06-26T20:30:03.000Z","date":"2026-06-25","kind":"sale","planned":true,"acquired":false,"shares":2867,"price":45.03,"value":129101.01,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on May 29, 2025."}],"balance_after":174633,"source":{"system":"sec-edgar","filing":"0001193125-26-285558","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000119312526285558/ownership.xml","form_type":"4"}},{"id":730577,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":24155,"kind":"person","name":"Wiley Matthew T.","position":1,"cik":"0001759703","reported_name":"Wiley Matthew T.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Shares","published_at":"2026-06-22T13:45:06.000Z","date":"2026-06-22","kind":"grant","planned":false,"acquired":true,"shares":62500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The common shares represent the first tranche of performance share units granted effective March 17, 2025, and remain subject to vesting based on the Reporting Person's continued employment through March 17, 2028. Each performance\nshare unit represented a contingent right to receive one common share based on, and subject to, the achievement of certain clinical and regulatory milestones set forth in the Performance Share Unit Award Agreement."}],"balance_after":177500,"source":{"system":"sec-edgar","filing":"0001193125-26-276881","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000119312526276881/ownership.xml","form_type":"4"}},{"id":917826,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":24155,"kind":"person","name":"Wiley Matthew T.","position":1,"cik":"0001759703","reported_name":"Wiley Matthew T.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Shares","published_at":"2026-02-05T22:00:10.000Z","date":"2026-02-03","kind":"grant","planned":false,"acquired":true,"shares":115000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one common share of the Issuer. The RSUs vest in 16 equal quarterly installments beginning on June 1, 2026, subject to the Reporting Person providing continuous service to the Issuer on each such vesting date."}],"balance_after":115000,"source":{"system":"sec-edgar","filing":"0001193125-26-039598","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000119312526039598/ownership.xml","form_type":"4"}},{"id":1185895,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":24155,"kind":"person","name":"Wiley Matthew T.","position":1,"cik":"0001759703","reported_name":"Wiley Matthew T.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2025-04-01T22:06:16.000Z","date":"2024-07-22","kind":"grant","planned":false,"acquired":true,"shares":1875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The share amount has been adjusted to reflect the reverse stock split effective on February 7, 2025 whereby every sixteen shares issued and outstanding prior to the split were combined and converted into one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Reporting Person was granted an option to purchase 1,875 shares of common stock, which vests as to 50% on each of the first and second anniversaries of the grant date, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Due to the Reporting Person's termination of employment, the unvested Stock Option was forfeited."}],"balance_after":1875,"derivative":{"exercise_price":1.2,"expiration_date":"2034-07-22","underlying":"Common Stock","underlying_shares":1875},"source":{"system":"sec-edgar","filing":"0001104659-25-030684","document":"tm2511097-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465925030684/tm2511097-4_4seq1.xml","form_type":"4"}},{"id":1200166,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":24155,"kind":"person","name":"Wiley Matthew T.","position":1,"cik":"0001759703","reported_name":"Wiley Matthew T.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-18T20:45:05.000Z","date":"2025-03-17","kind":"grant","planned":false,"acquired":true,"shares":350000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option shall vest and become exercisable over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such vesting date"}],"balance_after":350000,"derivative":{"exercise_price":6.35,"expiration_date":"2035-03-16","underlying":"Common Shares","underlying_shares":350000},"source":{"system":"sec-edgar","filing":"0000950170-25-041302","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000095017025041302/ownership.xml","form_type":"4"}},{"id":1391370,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":24155,"kind":"person","name":"Wiley Matthew T.","position":1,"cik":"0001759703","reported_name":"Wiley Matthew T.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2024-10-04T01:55:39.000Z","date":"2024-10-03","kind":"sale","planned":true,"acquired":false,"shares":6272,"price":0.55,"value":3449.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2023."}],"balance_after":19011,"source":{"system":"sec-edgar","filing":"0001104659-24-106064","document":"tm2425607-7_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465924106064/tm2425607-7_4seq1.xml","form_type":"4"}},{"id":1391369,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":24155,"kind":"person","name":"Wiley Matthew T.","position":1,"cik":"0001759703","reported_name":"Wiley Matthew T.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2024-10-04T01:55:39.000Z","date":"2024-09-17","kind":"grant","planned":true,"acquired":true,"shares":21250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Issuer previously granted the Reporting Person an award of restricted stock units that would vest based on the Issuer's satisfaction of certain performance objectives and subject to the Reporting Person's continued service with the Issuer through October 1, 2024 (the \"PSUs\"). On September 17, 2024, the Compensation Committee of the Issuer's Board of Directors determined that performance conditions with respect to 21,250 PSUs had been satisfied and 21,250 shares of common stock became issuable to the Reporting Person on October 1, 2024."}],"balance_after":25283,"source":{"system":"sec-edgar","filing":"0001104659-24-106064","document":"tm2425607-7_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465924106064/tm2425607-7_4seq1.xml","form_type":"4"}},{"id":1404516,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":24155,"kind":"person","name":"Wiley Matthew T.","position":1,"cik":"0001759703","reported_name":"Wiley Matthew T.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2024-09-17T23:18:35.000Z","date":"2024-09-15","kind":"exercise","planned":true,"acquired":false,"shares":750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On March 15, 2023, the Reporting Person was granted 12,000 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of Restricted Stock Units at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On March 15, 2023, the Reporting Person was granted 12,000 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of Restricted Stock Units at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":7500,"derivative":{"underlying":"Common Stock","underlying_shares":750},"source":{"system":"sec-edgar","filing":"0001104659-24-100746","document":"tm2424255-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465924100746/tm2424255-5_4seq1.xml","form_type":"4"}},{"id":1404515,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":24155,"kind":"person","name":"Wiley Matthew T.","position":1,"cik":"0001759703","reported_name":"Wiley Matthew T.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2024-09-17T23:18:35.000Z","date":"2024-09-16","kind":"sale","planned":true,"acquired":false,"shares":215,"price":0.6908,"value":148.522,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2023."}],"balance_after":4033,"source":{"system":"sec-edgar","filing":"0001104659-24-100746","document":"tm2424255-5_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465924100746/tm2424255-5_4seq1.xml","form_type":"4"}},{"id":1404514,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":24155,"kind":"person","name":"Wiley Matthew T.","position":1,"cik":"0001759703","reported_name":"Wiley Matthew T.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2024-09-17T23:18:35.000Z","date":"2024-09-15","kind":"exercise","planned":true,"acquired":true,"shares":750,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":4248,"source":{"system":"sec-edgar","filing":"0001104659-24-100746","document":"tm2424255-5_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465924100746/tm2424255-5_4seq1.xml","form_type":"4"}},{"id":1404513,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":24155,"kind":"person","name":"Wiley Matthew T.","position":1,"cik":"0001759703","reported_name":"Wiley Matthew T.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2024-09-17T23:17:50.000Z","date":"2024-06-15","kind":"exercise","planned":false,"acquired":false,"shares":750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On March 15, 2023, the Reporting Person was granted 12,000 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of Restricted Stock Units at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On March 15, 2023, the Reporting Person was granted 12,000 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of Restricted Stock Units at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":8250,"derivative":{"underlying":"Common Stock","underlying_shares":750},"source":{"system":"sec-edgar","filing":"0001104659-24-100745","document":"tm2424255-4_4aseq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465924100745/tm2424255-4_4aseq1.xml","form_type":"4/A","original_submission_date":"2024-06-18"}},{"id":1474426,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":24155,"kind":"person","name":"Wiley Matthew T.","position":1,"cik":"0001759703","reported_name":"Wiley Matthew T.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2024-06-19T01:26:34.000Z","date":"2024-06-15","kind":"exercise","planned":true,"acquired":true,"shares":750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On March 15, 2023, the Reporting Person was granted 12,000 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of Restricted Stock Units at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On March 15, 2023, the Reporting Person was granted 12,000 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of Restricted Stock Units at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":8250,"derivative":{"underlying":"Common Stock","underlying_shares":750},"source":{"system":"sec-edgar","filing":"0001104659-24-073003","document":"tm2417544-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465924073003/tm2417544-6_4seq1.xml","form_type":"4"}},{"id":1474425,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":24155,"kind":"person","name":"Wiley Matthew T.","position":1,"cik":"0001759703","reported_name":"Wiley Matthew T.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2024-06-19T01:26:34.000Z","date":"2024-06-17","kind":"sale","planned":true,"acquired":false,"shares":244,"price":1.2627,"value":308.0988,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2023."}],"balance_after":3498,"source":{"system":"sec-edgar","filing":"0001104659-24-073003","document":"tm2417544-6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465924073003/tm2417544-6_4seq1.xml","form_type":"4"}},{"id":1474424,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":24155,"kind":"person","name":"Wiley Matthew T.","position":1,"cik":"0001759703","reported_name":"Wiley Matthew T.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2024-06-19T01:26:34.000Z","date":"2024-06-15","kind":"exercise","planned":true,"acquired":true,"shares":750,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":3742,"source":{"system":"sec-edgar","filing":"0001104659-24-073003","document":"tm2417544-6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465924073003/tm2417544-6_4seq1.xml","form_type":"4"}},{"id":1545159,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":24155,"kind":"person","name":"Wiley Matthew T.","position":1,"cik":"0001759703","reported_name":"Wiley Matthew T.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF COMMERCIAL OFFICER"}}],"security":"Restricted Stock Units","published_at":"2024-04-08T23:31:35.000Z","date":"2024-03-15","kind":"exercise","planned":true,"acquired":true,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs will vest and settle as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of Restricted Stock Units at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The RSUs will vest and settle as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of Restricted Stock Units at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":9000,"derivative":{"underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001104659-24-044859","document":"tm2411220-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465924044859/tm2411220-3_4seq1.xml","form_type":"4"}},{"id":1545158,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":24155,"kind":"person","name":"Wiley Matthew T.","position":1,"cik":"0001759703","reported_name":"Wiley Matthew T.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF COMMERCIAL OFFICER"}}],"security":"Common Stock","published_at":"2024-04-08T23:31:35.000Z","date":"2024-04-04","kind":"sale","planned":true,"acquired":false,"shares":1008,"price":2.6351,"value":2656.1808,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $2.62 to $2.6502. The Reporting Person undertakes to provide upon request the Securities and Exchange Commission staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."}],"balance_after":2992,"source":{"system":"sec-edgar","filing":"0001104659-24-044859","document":"tm2411220-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465924044859/tm2411220-3_4seq1.xml","form_type":"4"}},{"id":1545157,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":24155,"kind":"person","name":"Wiley Matthew T.","position":1,"cik":"0001759703","reported_name":"Wiley Matthew T.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF COMMERCIAL OFFICER"}}],"security":"Common Stock","published_at":"2024-04-08T23:31:35.000Z","date":"2024-03-15","kind":"exercise","planned":true,"acquired":true,"shares":3000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":3000,"source":{"system":"sec-edgar","filing":"0001104659-24-044859","document":"tm2411220-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465924044859/tm2411220-3_4seq1.xml","form_type":"4"}},{"id":1949526,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":24155,"kind":"person","name":"Wiley Matthew T.","position":1,"cik":"0001759703","reported_name":"Wiley Matthew T.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF COMMERCIAL OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-16T21:58:56.000Z","date":"2023-03-15","kind":"grant","acquired":true,"shares":36000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vests and becomes exercisable as to 25% of the underlying shares on the first anniversary of March 15, 2023 and the remaining 75% of the underlying shares in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":36000,"derivative":{"exercise_price":19.6,"expiration_date":"2033-03-15","underlying":"Common Stock","underlying_shares":36000},"source":{"system":"sec-edgar","filing":"0001104659-23-033401","document":"tm239796-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465923033401/tm239796-2_4seq1.xml","form_type":"4"}},{"id":1949525,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":24155,"kind":"person","name":"Wiley Matthew T.","position":1,"cik":"0001759703","reported_name":"Wiley Matthew T.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF COMMERCIAL OFFICER"}}],"security":"Restricted Stock Units","published_at":"2023-03-16T21:58:56.000Z","date":"2023-03-15","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs will vest and settle as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of Restricted Stock Units at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs will vest and settle as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of Restricted Stock Units at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":12000,"derivative":{"underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001104659-23-033401","document":"tm239796-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465923033401/tm239796-2_4seq1.xml","form_type":"4"}},{"id":2431752,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":24155,"kind":"person","name":"Wiley Matthew T.","position":1,"cik":"0001759703","reported_name":"Wiley Matthew T.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF COMMERCIAL OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-01-19T21:19:39.000Z","date":"2022-01-17","kind":"grant","acquired":true,"shares":85000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable as to 25% of the underlying shares on the first anniversary of January 17, 2022 and the remaining 75% of the underlying shares in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":85000,"derivative":{"exercise_price":19.5,"expiration_date":"2032-01-16","underlying":"Common Stock","underlying_shares":85000},"source":{"system":"sec-edgar","filing":"0001104659-22-005451","document":"tm223835-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465922005451/tm223835-2_4seq1.xml","form_type":"4"}},{"id":2643667,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":24155,"kind":"person","name":"Wiley Matthew T.","position":1,"cik":"0001759703","reported_name":"Wiley Matthew T.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-07-02T20:36:53.000Z","date":"2021-06-30","kind":"tax_withholding","acquired":false,"shares":5151,"price":3.51,"value":18080.01,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units."}],"balance_after":109246,"source":{"system":"sec-edgar","filing":"0001209191-21-044980","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919121044980/doc4.xml","form_type":"4"}},{"id":2760440,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":24155,"kind":"person","name":"Wiley Matthew T.","position":1,"cik":"0001759703","reported_name":"Wiley Matthew T.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-04-02T16:15:28.000Z","date":"2021-03-31","kind":"tax_withholding","acquired":false,"shares":2573,"price":6.84,"value":17599.32,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units."}],"balance_after":114397,"source":{"system":"sec-edgar","filing":"0001209191-21-024412","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919121024412/doc4.xml","form_type":"4"}},{"id":2835142,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":24155,"kind":"person","name":"Wiley Matthew T.","position":1,"cik":"0001759703","reported_name":"Wiley Matthew T.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Options","published_at":"2021-02-24T21:40:08.000Z","date":"2021-02-22","kind":"grant","acquired":true,"shares":64575,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The awards vest over four years, 25% on March 31, 2022 and 6.25% every three months thereafter, ending on March 31, 2025."}],"balance_after":64575,"derivative":{"exercise_price":8.33,"expiration_date":"2031-02-22","underlying":"Common Stock","underlying_shares":64575},"source":{"system":"sec-edgar","filing":"0001209191-21-013821","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919121013821/doc4.xml","form_type":"4"}},{"id":2835141,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":24155,"kind":"person","name":"Wiley Matthew T.","position":1,"cik":"0001759703","reported_name":"Wiley Matthew T.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-02-24T21:40:08.000Z","date":"2021-02-22","kind":"grant","acquired":true,"shares":27675,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock unit awards, each of which by its terms represents a contingent right to receive one share of common stock of VYNE Therapeutics Inc."},{"field":"shares","element":"transactionShares","label":"F2","text":"The awards vest over four years, 25% on March 31, 2022 and 6.25% every three months thereafter, ending on March 31, 2025."}],"balance_after":116970,"source":{"system":"sec-edgar","filing":"0001209191-21-013821","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919121013821/doc4.xml","form_type":"4"}},{"id":2918931,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":24155,"kind":"person","name":"Wiley Matthew T.","position":1,"cik":"0001759703","reported_name":"Wiley Matthew T.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-01-05T21:32:46.000Z","date":"2020-12-31","kind":"tax_withholding","acquired":false,"shares":1541,"price":1.58,"value":2434.78,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units."}],"balance_after":357181,"source":{"system":"sec-edgar","filing":"0001209191-21-001097","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919121001097/doc4.xml","form_type":"4"}},{"id":2960108,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":24155,"kind":"person","name":"Wiley Matthew T.","position":1,"cik":"0001759703","reported_name":"Wiley Matthew T.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2020-12-02T21:31:39.000Z","date":"2020-11-30","kind":"grant","acquired":true,"shares":7838,"price":1.445,"value":11325.91,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were acquired under the Issuer's Employee Share Purchase Plan (\"ESPP\") for the ESPP purchase period beginning on April 1, 2020 and ending on November 30, 2020 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the fair market value closing price of the Issuer's ordinary shares on November 30, 2020 (the last trading day of the offering period). The reporting person purchased the maximum number of shares permitted by the terms of the ESPP during the calendar year."}],"balance_after":358722,"source":{"system":"sec-edgar","filing":"0001209191-20-061177","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919120061177/doc4.xml","form_type":"4"}},{"id":3015469,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":24155,"kind":"person","name":"Wiley Matthew T.","position":1,"cik":"0001759703","reported_name":"Wiley Matthew T.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2020-10-02T20:32:39.000Z","date":"2020-09-30","kind":"tax_withholding","acquired":false,"shares":1541,"price":1.66,"value":2558.06,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units."}],"balance_after":350884,"source":{"system":"sec-edgar","filing":"0001209191-20-053159","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919120053159/doc4.xml","form_type":"4"}},{"id":3090813,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":24155,"kind":"person","name":"Wiley Matthew T.","position":1,"cik":"0001759703","reported_name":"Wiley Matthew T.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2020-07-02T20:25:47.000Z","date":"2020-06-30","kind":"tax_withholding","acquired":false,"shares":1541,"price":1.73,"value":2665.93,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units."}],"balance_after":352425,"source":{"system":"sec-edgar","filing":"0001209191-20-040308","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919120040308/doc4.xml","form_type":"4"}},{"id":3156001,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":24155,"kind":"person","name":"Wiley Matthew T.","position":1,"cik":"0001759703","reported_name":"Wiley Matthew T.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Options","published_at":"2020-05-08T21:54:48.000Z","date":"2020-05-06","kind":"grant","acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The awards vest over four years, 25% on June 30, 2021 and 6.25% every three months thereafter, ending on June 30, 2024."}],"balance_after":150000,"derivative":{"exercise_price":1.95,"expiration_date":"2030-05-06","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001209191-20-028039","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919120028039/doc4.xml","form_type":"4"}},{"id":3156000,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":24155,"kind":"person","name":"Wiley Matthew T.","position":1,"cik":"0001759703","reported_name":"Wiley Matthew T.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2020-05-08T21:54:48.000Z","date":"2020-05-06","kind":"grant","acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock unit awards, each of which by its terms represents a contingent right to receive one share of common stock of Menlo Therapeutics Inc."},{"field":"shares","element":"transactionShares","label":"F2","text":"The awards vest over four years, 25% on June 30, 2021 and 6.25% every three months thereafter, ending on June 30, 2024."}],"balance_after":353967,"source":{"system":"sec-edgar","filing":"0001209191-20-028039","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919120028039/doc4.xml","form_type":"4"}},{"id":3180287,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":24155,"kind":"person","name":"Wiley Matthew T.","position":1,"cik":"0001759703","reported_name":"Wiley Matthew T.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2020-04-07T21:23:23.000Z","date":"2020-04-06","kind":"tax_withholding","acquired":false,"shares":908,"price":1.4,"value":1271.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units."}],"balance_after":203967,"source":{"system":"sec-edgar","filing":"0001209191-20-023813","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919120023813/doc4.xml","form_type":"4"}},{"id":3180286,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":24155,"kind":"person","name":"Wiley Matthew T.","position":1,"cik":"0001759703","reported_name":"Wiley Matthew T.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2020-04-07T21:23:23.000Z","date":"2020-04-03","kind":"grant","acquired":true,"shares":91430,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents restricted stock unit awards, each of which by its terms represents a contingent right to receive one share of common stock of Menlo."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"As disclosed by the Issuer in its Current Report on Form 8-K filed with the Securities and Exchange Commission on April 6, 2020, following the receipt of certain clinical trial results, Menlo Therapeutics Inc. (\"Menlo\") issued additional shares of its common stock pursuant to certain contingent stock rights (\"CSRs\") issued in connection with the March 9, 2020 merger (the \"Merger\") of Menlo and Foamix Pharmaceuticals Ltd. (\"Foamix\"), including pursuant to CSRs held by the Reporting Person. The issuance of shares pursuant to the CSRs resulted in an adjustment to the effective exchange ratio applicable to the Merger, from 0.5924 to 1.8006 (the \"Final Exchange Ratio\"). Menlo derivative securities issued in exchange for Foamix derivative securities in connection with the Merger were also adjusted pursuant to their terms to give effect to the Final Exchange Ratio. The transactions reported in these line items reflect the additional shares and restricted stock unit (continued in footnote 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from footnote 1) awards that were received by the reporting person as a result of the foregoing."}],"balance_after":204875,"source":{"system":"sec-edgar","filing":"0001209191-20-023813","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919120023813/doc4.xml","form_type":"4"}},{"id":3180285,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":24155,"kind":"person","name":"Wiley Matthew T.","position":1,"cik":"0001759703","reported_name":"Wiley Matthew T.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2020-04-07T21:23:23.000Z","date":"2020-04-03","kind":"grant","acquired":true,"shares":46394,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"As disclosed by the Issuer in its Current Report on Form 8-K filed with the Securities and Exchange Commission on April 6, 2020, following the receipt of certain clinical trial results, Menlo Therapeutics Inc. (\"Menlo\") issued additional shares of its common stock pursuant to certain contingent stock rights (\"CSRs\") issued in connection with the March 9, 2020 merger (the \"Merger\") of Menlo and Foamix Pharmaceuticals Ltd. (\"Foamix\"), including pursuant to CSRs held by the Reporting Person. The issuance of shares pursuant to the CSRs resulted in an adjustment to the effective exchange ratio applicable to the Merger, from 0.5924 to 1.8006 (the \"Final Exchange Ratio\"). Menlo derivative securities issued in exchange for Foamix derivative securities in connection with the Merger were also adjusted pursuant to their terms to give effect to the Final Exchange Ratio. The transactions reported in these line items reflect the additional shares and restricted stock unit (continued in footnote 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from footnote 1) awards that were received by the reporting person as a result of the foregoing."}],"balance_after":113445,"source":{"system":"sec-edgar","filing":"0001209191-20-023813","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919120023813/doc4.xml","form_type":"4"}},{"id":3185765,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":24155,"kind":"person","name":"Wiley Matthew T.","position":1,"cik":"0001759703","reported_name":"Wiley Matthew T.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2020-04-02T20:41:39.000Z","date":"2020-03-31","kind":"tax_withholding","acquired":false,"shares":525,"price":2.68,"value":1407.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units."}],"balance_after":67051,"source":{"system":"sec-edgar","filing":"0001209191-20-022591","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919120022591/doc4.xml","form_type":"4"}},{"id":3215147,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":24155,"kind":"person","name":"Wiley Matthew T.","position":1,"cik":"0001759703","reported_name":"Wiley Matthew T.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Options","published_at":"2020-03-11T21:57:55.000Z","date":"2020-03-09","kind":"grant","acquired":true,"shares":57086,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in or in connection with the merger of Foamix Pharmaceuticals Ltd.  (\"Foamix\"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo Therapeutics Inc. (\"Menlo\"), in exchange for Foamix equity securities, as further described in the Form 4 filed by the Reporting Person on the date hereof in respect of the Reporting Person's interests in Foamix equity securities. The Reporting Person also received certain contingent stock rights which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo, or related contractual interests, either of which may entitle the Reporting Person to certain additional Menlo equity securities or the adjustment of certain Menlo equity securities, all as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The ordinary shares underlying this option vest over a period of four years (25% on March 31, 2021 and 6.25% every three months thereafter) ending March 31, 2024."}],"balance_after":57086,"derivative":{"exercise_price":6.81,"expiration_date":"2030-02-24","underlying":"Common Stock","underlying_shares":57086},"source":{"system":"sec-edgar","filing":"0001209191-20-018229","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919120018229/doc4.xml","form_type":"4"}},{"id":3215146,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":24155,"kind":"person","name":"Wiley Matthew T.","position":1,"cik":"0001759703","reported_name":"Wiley Matthew T.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Options","published_at":"2020-03-11T21:57:55.000Z","date":"2020-03-09","kind":"grant","acquired":true,"shares":59240,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in or in connection with the merger of Foamix Pharmaceuticals Ltd.  (\"Foamix\"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo Therapeutics Inc. (\"Menlo\"), in exchange for Foamix equity securities, as further described in the Form 4 filed by the Reporting Person on the date hereof in respect of the Reporting Person's interests in Foamix equity securities. The Reporting Person also received certain contingent stock rights which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo, or related contractual interests, either of which may entitle the Reporting Person to certain additional Menlo equity securities or the adjustment of certain Menlo equity securities, all as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The ordinary shares underlying this option vest over a period of four years (25% on December 31, 2019 and 6.25% every three months thereafter) ending December 31, 2022."}],"balance_after":59240,"derivative":{"exercise_price":6.86,"expiration_date":"2028-12-03","underlying":"Common Stock","underlying_shares":59240},"source":{"system":"sec-edgar","filing":"0001209191-20-018229","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919120018229/doc4.xml","form_type":"4"}},{"id":3215145,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":24155,"kind":"person","name":"Wiley Matthew T.","position":1,"cik":"0001759703","reported_name":"Wiley Matthew T.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2020-03-11T21:57:55.000Z","date":"2020-03-09","kind":"grant","acquired":true,"shares":46680,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents restricted stock unit awards, each of which by its terms represents a contingent right to receive one share of common stock of Menlo."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in or in connection with the merger of Foamix Pharmaceuticals Ltd.  (\"Foamix\"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo Therapeutics Inc. (\"Menlo\"), in exchange for Foamix equity securities, as further described in the Form 4 filed by the Reporting Person on the date hereof in respect of the Reporting Person's interests in Foamix equity securities. The Reporting Person also received certain contingent stock rights which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo, or related contractual interests, either of which may entitle the Reporting Person to certain additional Menlo equity securities or the adjustment of certain Menlo equity securities, all as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020."}],"balance_after":67576,"source":{"system":"sec-edgar","filing":"0001209191-20-018229","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919120018229/doc4.xml","form_type":"4"}},{"id":3215144,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":24155,"kind":"person","name":"Wiley Matthew T.","position":1,"cik":"0001759703","reported_name":"Wiley Matthew T.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2020-03-11T21:57:55.000Z","date":"2020-03-09","kind":"grant","acquired":true,"shares":20896,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in or in connection with the merger of Foamix Pharmaceuticals Ltd.  (\"Foamix\"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo Therapeutics Inc. (\"Menlo\"), in exchange for Foamix equity securities, as further described in the Form 4 filed by the Reporting Person on the date hereof in respect of the Reporting Person's interests in Foamix equity securities. The Reporting Person also received certain contingent stock rights which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo, or related contractual interests, either of which may entitle the Reporting Person to certain additional Menlo equity securities or the adjustment of certain Menlo equity securities, all as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020."}],"balance_after":20896,"source":{"system":"sec-edgar","filing":"0001209191-20-018229","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919120018229/doc4.xml","form_type":"4"}},{"id":3215021,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":24155,"kind":"person","name":"Wiley Matthew T.","position":1,"cik":"0001759703","reported_name":"Wiley Matthew T.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Options","published_at":"2020-03-11T17:41:43.000Z","date":"2020-03-09","kind":"disposition_to_issuer","acquired":false,"shares":96365,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"At the Effective Time, each option to purchase a Foamix Share (a \"Foamix Option\") was converted into an option to purchase Menlo Common Stock (an \"Adjusted Option\") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The ordinary shares underlying this option vest over a period of four years (25% on March 31, 2021 and 6.25% every three months thereafter) ending March 31, 2024."}],"balance_after":0,"derivative":{"exercise_price":4.03,"expiration_date":"2030-02-24","underlying":"Ordinary Shares","underlying_shares":96365},"source":{"system":"sec-edgar","filing":"0001209191-20-018204","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000120919120018204/doc4.xml","form_type":"4"}},{"id":3215020,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":24155,"kind":"person","name":"Wiley Matthew T.","position":1,"cik":"0001759703","reported_name":"Wiley Matthew T.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Options","published_at":"2020-03-11T17:41:43.000Z","date":"2020-03-09","kind":"disposition_to_issuer","acquired":false,"shares":100000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"At the Effective Time, each option to purchase a Foamix Share (a \"Foamix Option\") was converted into an option to purchase Menlo Common Stock (an \"Adjusted Option\") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The ordinary shares underlying this option vest over a period of four years (25% on December 31, 2019 and 6.25% every three months thereafter) ending December 31, 2022."}],"balance_after":0,"derivative":{"exercise_price":4.06,"expiration_date":"2028-12-03","underlying":"Ordinary Shares","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001209191-20-018204","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000120919120018204/doc4.xml","form_type":"4"}},{"id":3215019,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":24155,"kind":"person","name":"Wiley Matthew T.","position":1,"cik":"0001759703","reported_name":"Wiley Matthew T.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Ordinary Shares","published_at":"2020-03-11T17:41:43.000Z","date":"2020-03-09","kind":"disposition_to_issuer","acquired":false,"shares":78799,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents Foamix restricted stock unit awards (\"Foamix RSUs\") that were outstanding immediately prior to the Effective Time, each of which by its terms represented a contingent right to receive one Foamix Share. Each Foamix RSU was assumed by Menlo and converted into a restricted stock unit award relating to Menlo Common Stock (an \"Adjusted RSU Award\") and has the same terms and conditions as applied to the Foamix RSU immediately prior to the Effective Time. The Adjusted RSU Award will settle in the number of shares of Menlo Common Stock equal to the product obtained by multiplying (i) the number of Foamix Shares subject to the Foamix RSU immediately prior to the Effective Time by (ii) the Exchange Ratio. If the CSRs become convertible, each person holding a Foamix RSU immediately prior to the Effective Time will get additional Adjusted RSU Awards based on the additional shares of Menlo Common Stock that each ordinary Foamix Share will get upon conversion of a CSR."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-20-018204","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000120919120018204/doc4.xml","form_type":"4"}},{"id":3215018,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":24155,"kind":"person","name":"Wiley Matthew T.","position":1,"cik":"0001759703","reported_name":"Wiley Matthew T.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Ordinary Shares","published_at":"2020-03-11T17:41:43.000Z","date":"2020-03-09","kind":"disposition_to_issuer","acquired":false,"shares":35275,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 9, 2020 (the \"Closing Date\"), pursuant to the Agreement and Plan of Merger, dated as of November 10, 2019, as amended on December 4, 2019 (as amended, the \"Merger Agreement\"), by and among Menlo Therapeutics Inc., a Delaware corporation (\"Menlo\"), Foamix Pharmaceuticals Ltd., a company organized under the laws of Israel (\"Foamix\"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo (\"Merger Sub\"), Merger Sub merged with and into Foamix, with Foamix surviving as a wholly owned subsidiary of Menlo (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), each ordinary share, par value NIS 0.16 per share, of Foamix (\"Foamix Shares\") issued and outstanding immediately prior to the Effective Time was deemed transferred under Israeli law to Menlo in exchange for the right to receive (i) 0.5924 shares (the \"Exchange Ratio\") of common stock of Menlo (\"Menlo Common Stock\") and (ii) one contingent stock right (continued in footnote 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(a \"CSR\"; and collectively, the \"CSRs\") which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo (the \"CSR Agreement\"), as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020 (collectively, the \"Merger Consideration\"). The closing price of a share of Menlo Common Stock on March 6, 2020, the last trading day before the Effective Time, was $4.15. No fractional share of Menlo Common Stock was issued in the Merger, and Foamix shareholders received cash in lieu of fractional shares, as specified in the Merger Agreement."}],"balance_after":78799,"source":{"system":"sec-edgar","filing":"0001209191-20-018204","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000120919120018204/doc4.xml","form_type":"4"}},{"id":3230635,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":24155,"kind":"person","name":"Wiley Matthew T.","position":1,"cik":"0001759703","reported_name":"Wiley Matthew T.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Ordinary Shares","published_at":"2020-03-03T16:39:27.000Z","date":"2020-03-02","kind":"grant","acquired":true,"shares":1993,"price":2.6775,"value":5336.2575,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were acquired under the Foamix Pharmaceuticals Ltd. Employee Share Purchase Plan (\"ESPP\") for the ESPP purchase period beginning on December 1, 2019 and ending on March 2, 2020 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the fair market value closing price of the Issuer's ordinary shares on December 2, 2019 (the first trading day of the offering period)."}],"balance_after":114074,"source":{"system":"sec-edgar","filing":"0001209191-20-015241","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000120919120015241/doc4.xml","form_type":"4"}},{"id":3251942,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":24155,"kind":"person","name":"Wiley Matthew T.","position":1,"cik":"0001759703","reported_name":"Wiley Matthew T.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Options","published_at":"2020-02-24T18:39:46.000Z","date":"2020-02-24","kind":"grant","acquired":true,"shares":96365,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"Each option represents a contingent right to purchase one ordinary share of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The ordinary shares underlying these options vest over a 4 year period, with 25% vesting on the first anniversary of the last day of the calendar quarter in which the grant occurred and 6.25% vesting on the last day of each subsequent calendar quarter, ending March 31, 2024."}],"balance_after":96365,"derivative":{"exercise_price":4.03,"expiration_date":"2030-02-24","underlying":"Ordinary Shares","underlying_shares":96365},"source":{"system":"sec-edgar","filing":"0001209191-20-012200","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000120919120012200/doc4.xml","form_type":"4"}},{"id":3251941,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":24155,"kind":"person","name":"Wiley Matthew T.","position":1,"cik":"0001759703","reported_name":"Wiley Matthew T.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Ordinary Shares","published_at":"2020-02-24T18:39:46.000Z","date":"2020-02-24","kind":"grant","acquired":true,"shares":41299,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This security represents restricted share units. Each restricted share unit represents a contingent right to receive one ordinary share of the issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"The ordinary shares underlying this restricted share unit award vest over a 4 year period, with 25% vesting on the first anniversary of the last day of the calendar quarter in which the grant occurred and 6.25% vesting on the last day of each subsequent calendar quarter, ending March 31, 2024."}],"balance_after":112081,"source":{"system":"sec-edgar","filing":"0001209191-20-012200","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000120919120012200/doc4.xml","form_type":"4"}},{"id":3321404,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":24155,"kind":"person","name":"Wiley Matthew T.","position":1,"cik":"0001759703","reported_name":"Wiley Matthew T.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Ordinary Shares","published_at":"2020-01-03T17:24:49.000Z","date":"2019-12-31","kind":"tax_withholding","acquired":false,"shares":2500,"price":3.28,"value":8200.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of the restricted share units and does not represent a sale by the Reporting Person."}],"balance_after":70782,"source":{"system":"sec-edgar","filing":"0001209191-20-001250","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000120919120001250/doc4.xml","form_type":"4"}},{"id":3353637,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":24155,"kind":"person","name":"Wiley Matthew T.","position":1,"cik":"0001759703","reported_name":"Wiley Matthew T.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Ordinary Shares","published_at":"2019-12-03T16:31:34.000Z","date":"2019-11-29","kind":"grant","acquired":true,"shares":9842,"price":2.159,"value":21248.878,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were acquired under the Foamix Pharmaceuticals Ltd. Employee Share Purchase Plan (\"ESPP\") for the ESPP purchase period beginning on June 1, 2019 and ending on December 1, 2019 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the fair market value closing price of the Issuer's ordinary shares on June 3, 2019 (the first trading day of the offering period). The reporting person purchased the maximum number of shares permitted by the terms of the ESPP during the offering period."}],"balance_after":73282,"source":{"system":"sec-edgar","filing":"0001209191-19-058712","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000120919119058712/doc4.xml","form_type":"4"}},{"id":3607768,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":24155,"kind":"person","name":"Wiley Matthew T.","position":1,"cik":"0001759703","reported_name":"Wiley Matthew T.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Ordinary Shares","published_at":"2019-03-06T16:07:30.000Z","date":"2019-03-05","kind":"purchase","acquired":true,"shares":13440,"price":3.76,"value":50534.4,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.725 to $3.76 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4."}],"balance_after":63440,"source":{"system":"sec-edgar","filing":"0001209191-19-017304","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000120919119017304/doc4.xml","form_type":"4"}},{"id":3743177,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":24155,"kind":"person","name":"Wiley Matthew T.","position":1,"cik":"0001759703","reported_name":"Wiley Matthew T.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Options","published_at":"2018-12-04T16:05:38.000Z","date":"2018-12-03","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F4","text":"Each option represents a contingent right to purchase one ordinary share of the issuer."},{"field":"date","element":"transactionDate","label":"F1","text":"The equity incentive grants were approved by the Issuer's board of directors on the recommendation of a committee of the board on November 14, 2018 with a grant date of December 3, 2018."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The ordinary shares underlying these options vest over a period of four years from the end of the calendar quarter in which the grant was made (25% on December 31, 2019 and 6.25% every three months thereafter) ending December 31, 2022."}],"balance_after":100000,"derivative":{"exercise_price":4.06,"expiration_date":"2028-12-03","underlying":"Ordinary Shares","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001178913-18-003085","document":"zk1822341.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000117891318003085/zk1822341.xml","form_type":"4"}},{"id":3743176,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":24155,"kind":"person","name":"Wiley Matthew T.","position":1,"cik":"0001759703","reported_name":"Wiley Matthew T.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Ordinary Shares","published_at":"2018-12-04T16:05:38.000Z","date":"2018-12-03","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The equity incentive grants were approved by the Issuer's board of directors on the recommendation of a committee of the board on November 14, 2018 with a grant date of December 3, 2018."},{"field":"shares","element":"transactionShares","label":"F2","text":"The ordinary shares underlying this restricted share unit award vest over a period of four years from the end of the calendar quarter in which the grant was made (25% on December 31, 2019 and 6.25% every three months thereafter) ending December 31, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This security represents restricted share units. Each restricted share unit represents a contingent right to receive one ordinary share of the issuer."}],"balance_after":50000,"source":{"system":"sec-edgar","filing":"0001178913-18-003085","document":"zk1822341.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000117891318003085/zk1822341.xml","form_type":"4"}}]}